Premium
Black β‐thalassemia homozygotes with specific sequence variations in the 5′ hypersensitive site‐2 of the locus control region have high levels of fetal hemoglobin
Author(s) -
Beris Ph.,
Kitundu M. N.,
Baysal E.,
Öner C.,
Lanclos K. D.,
Dimovski A. J.,
Kutlar F.,
Huisman T. H. J.
Publication year - 1992
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830410206
Subject(s) - haplotype , genetics , proband , biology , locus (genetics) , locus control region , promoter , hemoglobinopathy , fetal hemoglobin , globin , mutation , gene , microbiology and biotechnology , thalassemia , fetus , allele , hemolytic anemia , immunology , pregnancy , gene expression
We have sequenced the 5′ hypersensitive‐2 (5′HS‐2) site of the locus control region (LCR) and the promoters of the two γ‐globin genes located on chromosome 11 of a black patient with mild β‐thalassemia (β‐thal) major due to a homozygosity for the C → T mutation at position – 88 of the β promoter and with a high Hb F level. Sequence variations in the 5′HS‐2 were the same as observed for the β s chromosome with haplotype number 3, while most of the G γ promoter and the A γ promoter had sequences similar to that of the β s chromosome with haplotype number 19. This atypical haplotype (number 19A) is apparently associated with an increased γ chain production which is particularly evident during periods of severe hematopoietic stress. Additional studies on relatives of the proband and on 10 unrelated black β‐thal homozygotes with either the C → T mutation at – 88 or the A → G mutation at –29, confirm the possible importance of the sequence differences in the 5′HS‐2, and also suggest that at least two additional factors, namely a C → T mutation at position –158 of the G γ promoter and a relative deficiency in α chain synthesis play a (perhaps less important) role in the increased Hb F synthesis in these patients. © 1992 Wiley‐Liss, Inc.